

C34-PEG-4-Chol - a new fusion inhibitor for the treatment of HIV

Submission date 28/01/2015	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 29/01/2015	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 09/07/2018	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

HIV (human immunodeficiency virus) is a virus that damages a person's immune system, making them less able to fight infections and disease. There is no cure for the infection, but there are now some very effective treatments, called antiretrovirals, that stop the virus from replicating and therefore help infected people have long and healthy lives. The success of these treatments means that HIV-positive people are now aging. This poses new problems such as heart, kidney, bone and liver diseases which, although associated with ageing, may be more widespread due to the long-term side-effects of anti-HIV drugs. Additionally, drug-drug interactions become increasingly frequent and more complex when treating people who are on treatment for other problems. Therefore, developing new anti-HIV drugs, with less toxicity and likelihood for interactions, is critical. C34-PEG-4-Chol belongs to a family of anti-HIV medications called "fusion inhibitors". C34-PEG-4-Chol is similar to another drug in this family called enfuvirtide. Due to how it is broken down by the body enfuvirtide shows little general toxicity and few drug interactions. However it requires injection under the skin twice daily and injection site reactions are common. C34-PEG-4-Chol is expected to need injecting less frequently resulting in fewer reactions. This study will investigate whether giving this drug to humans is safe.

Who can participate?

HIV-positive men aged 18-60

What does the study involve?

Participants are randomly allocated into one of two groups. Those in group 1 are given C34-PEG-4-Chol. Those in group 2 are given a placebo. Samples from each participant are then collected at various time points. Stage 1 involves giving a single dose, allowing researchers to work out the best dose and how often to give it. Stage 2 involves giving 4 doses then checking how much drug gets into the bloodstream and how much the HIV level drops. Each stage should take about 6 months to complete.

What are the possible benefits and risks of participating?

There are no specific advantages of taking part in this study. Risks include side effects to C34-PEG4-Chol which may include injection site reactions (redness, swelling, feeling itchy, bruises, hardened skin or bumps, pain, feeling sore or tender), diarrhoea, nausea / vomiting, raised white

blood cell count, pneumonia, feeling weak or tired, headache, feeling dizzy, not being able to sleep, feeling anxious or low in mood, fever, weight loss, poor appetite, pain and feeling numb in hands, feet or legs, swollen glands (lymph nodes). However C34-PEG4-Chol has never been given to humans before so it is possible other unpredictable side effects could occur. As the study involves giving C34-PEG4-Chol without any other anti-HIV drugs, it is possible that HIV resistance to C34-PEG4-Chol could develop. This could also mean that resistance develops to enfuvirtide and any other fusion inhibitor drugs developed in the future. It is possible that if C34-PEG4-Chol were given to a person who was planning to become pregnant with their partner that it might harm an unborn child. Blood tests can sometimes cause bruising and soreness of the arms or, very rarely, a blockage of a vein or a small nerve injury which can cause numbness and pain. Normally these problems disappear with time. Some people may faint while the blood is being drawn.

Where is the study run from?

Imperial College Healthcare NHS Trust (UK)

When is the study starting and how long is it expected to run for?

February 2015 to November 2015

Who is funding the study?

Medical Research Council (UK)

Who is the main contact?

Mrs Nicki Doyle

Contact information

Type(s)

Scientific

Contact name

Mrs Nicki Doyle

Contact details

St Mary's Hospital
Imperial College Healthcare NHS Trust
10th Floor QEQM Building Imperial College
St Mary's Campus
South Wharf Road
London
United Kingdom
W2 1NY

Additional identifiers

EudraCT/CTIS number

2014-002671-28

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

17974

Study information

Scientific Title

A phase 1, first in man, study to assess the safety, pharmacokinetic profile and antiretroviral efficacy of C34-PEG-4-Chol, a novel peptide fusion inhibitor for the treatment of HIV infection

Study objectives

The aims of the study are:

1. To assess the safety, pharmacokinetics and pharmacodynamics of C34-PEG4-Chol in HIV-positive individuals.
2. To determine the optimal dose and dosing schedule for C34-PEG4-Chol.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee London - Central, 24/12/2014, ref: 14/LO/2078

Study design

Randomised; Interventional; Design type: Treatment

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: Infectious diseases and microbiology; Subtopic: Infection (all Subtopics); Disease: Infectious diseases and microbiology

Interventions

1. C34-PEG4-Chol (Peptivir-H), HIV fusion inhibitor
2. Placebo, sodium chloride 0.9% solution

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

C34-PEG-4-Chol

Primary outcome measure

1. Safety, pharmacokinetic & pharmacodynamic (viral decay - stage 2 only) parameters; Timepoint (s): Stage 1 - up to day 84 post-single dose
2. Stage 2 - follow up duration to be determined from stage 1

Secondary outcome measures

1. Changes in plasma HIV RNA; Timepoint(s): Stage 1 - measured up to day 28 post-single dose
2. Detailed pharmacokinetic profile of C34-PEG4-Chol when administered at different single doses. Timepoint(s): Stage 1 - profile at day 84 post-single dose
3. Detailed pharmacokinetic profile of C34-PEG4-Chol when administered following multiple dosing; Timepoint(s): Stage 2 - profile at final follow up (duration to be determined from stage 1)
4. Emergence of mutations within heptad repeat-1 (HR-1) region of gp41; Timepoint(s): Stage 2 - measured up to 4th follow up visit (duration of follow up to be determined from stage 1)
5. Listing of all adverse events (grade 1 and above); Timepoint(s): Stage 1-up to day 84 post-single dose
Stage 2-up to final follow up (fu determined from stage 1)

Overall study start date

23/07/2013

Completion date

01/04/2016

Eligibility

Key inclusion criteria

1. The ability to understand and sign a written informed consent form, prior to participation in any screening procedures, and be willing to comply with all study requirements
2. Male
3. Between 18 to 60 years, inclusive
4. Documented HIV-1 infected for ≥ 6 months from screening
5. Comorbidities, if present, optimally managed and stable
6. Normal physical examination
7. No clinically significant abnormalities on laboratory screening test
8. BMI 19-28, inclusive
9. Patients who are heterosexually active must agree to use two effective forms of contraception (e.g., condom with spermicide and established hormonal contraception) during heterosexual intercourse, from screening through to completion of the study
10. CD4 count ≥ 400 cells/ μ L at screening

11. Plasma HIV RNA \geq 10000 copies/mL at screening
12. In the opinion of the investigator not likely to require ART in the next 4 months
13. No clinically significant abnormalities on 12-lead ECG

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Male

Target number of participants

Planned Sample Size: 42; UK Sample Size: 42; Description: In stage 1 a maximum of 28 participants (20 active, 8 placebo) will be enrolled. In stage 2 a maximum of 14 participants (11 active, 3 placebo) will be enrolled.

Key exclusion criteria

1. Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with patient treatment, assessment, or compliance with the protocol. This would include any active clinically significant renal, cardiac, hepatic, pulmonary, vascular, metabolic (thyroid disorders, adrenal disease) disease immunodeficiency disorders, active infection, or malignancy
2. Participation in an investigational trial involving administration of any investigational compound within 90 days of screening
3. History of alcohol use considered by the investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should be expected to remain consistent throughout the study
4. History of recreational drug use within 14 days of screening or a positive drug screen on day of screening
5. Any medication taken listed in Section 8.3 of the protocol (Interaction with other drugs) including over-the-counter medications and herbal products, within 28 days of screening with the exception of vitamins and/or paracetamol. When a concomitant medication is necessary this will be reviewed by the investigator and if not contraindicated may be continued
6. History of drug sensitivity or drug allergy which in the opinion of the investigator may put the patient at increased risk of drug reactions during the study
7. Patients with female partners who are not using 2 effective forms of contraception or with partners who are pregnant
8. Documented resistance of clinical relevance to any other class of HIV antiretroviral drugs
9. Previous exposure to fusion inhibitors (T20/enfuvirtide)
10. Receiving ART within 6 months of screening

Date of first enrolment

01/03/2015

Date of final enrolment

01/12/2015

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

St Mary's Hospital

Imperial College Healthcare NHS Trust
10th Floor QEQM Building Imperial College
St Mary's Campus
South Wharf Road
London
United Kingdom
W2 1NY

Sponsor information

Organisation

Imperial College London

Sponsor details

Joint Research Compliance Office
Charing Cross Hospital
Fulham Palace Road
London
England
United Kingdom
W6 8RF

Sponsor type

University/education

ROR

<https://ror.org/041kmwe10>

Funder(s)

Funder type

Government

Funder Name

Medical Research Council

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

A meeting will be held at the end of the study to provide the results to participants who have taken part in the study. In addition results will be published in peer reviewed scientific journals and presented at conferences at the end of the study.

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	25/08/2017		Yes	No
HRA research summary			28/06/2023	No	No